Tajnoos Yazdany1, Narender Bhatia, John Nguyen. 1. Division of Female Pelvic Medicine and Reconstructive Surgery, David Geffen UCLA School of Medicine, 1000 W. Carson St, Torrance, CA 90509, Box 489, USA. tyazdany@obgyn.humc.edu
Abstract
INTRODUCTION AND HYPOTHESIS: The objective of this study was to determine the predictors of successful treatment of lower urinary tract disorders with sacral nerve stimulation (SNS) and the rate of adverse events and reoperations. METHODS: A retrospective case series of patients who underwent SNS at a single institution was analyzed. RESULTS: Seventy-six patients underwent stage I trial of SNS. Fifty-eight (76%) patients experienced improvement and underwent placement of an implantable pulse generator with a mean follow-up of 23.7 months (SD ± 22.3). Surgical revisions occurred in 14/58 (24%) patients and 15/58 (26%) patients had the device explanted after a mean of 2.8 years (SD ± 1.7). Patients with greater than ten incontinence episodes per day were more likely to have a successful stage I trial compared to those with less than five (OR = 10.3; 95% CI 2.1 to 50.60). CONCLUSIONS: Although SNS is a safe and effective therapy for lower urinary tract disorders, it is associated with a high reoperation rate.
INTRODUCTION AND HYPOTHESIS: The objective of this study was to determine the predictors of successful treatment of lower urinary tract disorders with sacral nerve stimulation (SNS) and the rate of adverse events and reoperations. METHODS: A retrospective case series of patients who underwent SNS at a single institution was analyzed. RESULTS: Seventy-six patients underwent stage I trial of SNS. Fifty-eight (76%) patients experienced improvement and underwent placement of an implantable pulse generator with a mean follow-up of 23.7 months (SD ± 22.3). Surgical revisions occurred in 14/58 (24%) patients and 15/58 (26%) patients had the device explanted after a mean of 2.8 years (SD ± 1.7). Patients with greater than ten incontinence episodes per day were more likely to have a successful stage I trial compared to those with less than five (OR = 10.3; 95% CI 2.1 to 50.60). CONCLUSIONS: Although SNS is a safe and effective therapy for lower urinary tract disorders, it is associated with a high reoperation rate.
Authors: R A Schmidt; U Jonas; K A Oleson; R A Janknegt; M M Hassouna; S W Siegel; P E van Kerrebroeck Journal: J Urol Date: 1999-08 Impact factor: 7.450
Authors: R C Bump; A Mattiasson; K Bø; L P Brubaker; J O DeLancey; P Klarskov; B L Shull; A R Smith Journal: Am J Obstet Gynecol Date: 1996-07 Impact factor: 8.661
Authors: W A Scheepens; M M G J Jongen; F H M Nieman; R A de Bie; E H J Weil; P E V van Kerrebroeck Journal: Urology Date: 2002-10 Impact factor: 2.649
Authors: Teh-Wei Hu; Todd H Wagner; Judith D Bentkover; Kristi LeBlanc; Amy Piancentini; Walter F Stewart; Ron Corey; Steve Z Zhou; Timothy L Hunt Journal: Urology Date: 2003-06 Impact factor: 2.649
Authors: Holly E Richter; C L Amundsen; S W Erickson; J E Jelovsek; Y Komesu; C Chermansky; H S Harvie; M Albo; D Myers; W T Gregory; D Wallace Journal: J Urol Date: 2017-05-10 Impact factor: 7.450
Authors: Ranjana Jairam; Jamie Drossaerts; Tom Marcelissen; Gommert van Koeveringe; Desiree Vrijens; Philip van Kerrebroeck Journal: Urol Int Date: 2021-05-31 Impact factor: 1.934
Authors: Jose Carlos Truzzi; Cristiano Mendes Gomes; Carlos A Bezerra; Ivan Mauricio Plata; Jose Campos; Gustavo Luis Garrido; Fernando G Almeida; Marcio Augusto Averbeck; Alexandre Fornari; Anibal Salazar; Arturo Dell'Oro; Caio Cintra; Carlos Alberto Ricetto Sacomani; Juan Pablo Tapia; Eduardo Brambila; Emilio Miguel Longo; Flavio Trigo Rocha; Francisco Coutinho; Gabriel Favre; Jose Antonio Garcia; Juan Castano; Miguel Reyes; Rodrigo Eugenio Leyton; Ruiter Silva Ferreira; Sergio Duran; Vanda Lopez; Ricardo Reges Journal: Int Braz J Urol Date: 2016 Mar-Apr Impact factor: 1.541
Authors: Tess van Doorn; Sarah H M Reuvers; Monique J Roobol; Sebastiaan Remmers; Jan F M Verbeek; Jeroen R Scheepe; Josien H Wolterbeek; Deric K E van der Schoot; Daan Nieboer; Lisette A 't Hoen; Bertil F M Blok Journal: Ther Adv Urol Date: 2022-04-20
Authors: Kristian D Stensland; Bennett Sluis; Jay Vance; Jared P Schober; Lara S MacLachlan; Arthur P Mourtzinos Journal: Int Neurourol J Date: 2018-09-28 Impact factor: 2.835